The Cancer Center Clinical Trials Office [CTO] is a centralized office for services to clinical investigators, providing a one-stop source for trial development and start-up, compliance with regulatory guidelines, and trial coordination. It is under the direction of the CTO Manager, Jane Eggleton, R.N., and the Medical Director, Peter Waldron, M.D., who report to Geoffrey Weiss, Deputy Director for Clinical Research and Clinical Affairs. The Cancer Center CTO Oversight Committee is responsible for monitoring the activities of the CTO and the other components of the cancer trials program at UVa. The physical space of the office is 1990 square feet, most of the space contiguous to the outpatient oncology clinic. The remainder of the CTO space is within the same building. The annual Institutional support for the CTO includes $350,000 of direct support, $75,000 in support of the CTO data base, and over $750,000 of philanthropic support for the CTO. Since the last competitive renewal, the CC leadership conducted a detailed review of the operations of the CTO and introduced a number of changes that have strengthened the CTO infrastructure and have greatly assisted clinical trialists in the design, opening, and management of trials. This includes personnel to assist with trials development and IND applications, an """"""""expediter"""""""" to facilitate regulatory management, and an emphasis on hiring and retaining experienced CRAs. As a result, the time to open a trial was shortened from 8 months to 3 months and the number of institutional trials was dramatically increased.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-17
Application #
7726762
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-02-01
Budget End
2008-01-31
Support Year
17
Fiscal Year
2007
Total Cost
$97,758
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437
Manukyan, Arkadi; Kowalczyk, Izabela; Melhuish, Tiffany A et al. (2018) Analysis of transcriptional activity by the Myt1 and Myt1l transcription factors. J Cell Biochem 119:4644-4655
Engelhard, Victor H; Rodriguez, Anthony B; Mauldin, Ileana S et al. (2018) Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. J Immunol 200:432-442
Martins, André L; Walavalkar, Ninad M; Anderson, Warren D et al. (2018) Universal correction of enzymatic sequence bias reveals molecular signatures of protein/DNA interactions. Nucleic Acids Res 46:e9
Michaels, Alex D; Newhook, Timothy E; Adair, Sara J et al. (2018) CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer. Clin Cancer Res 24:1415-1425
Shi, Lei; Li, Kang; Guo, Yizhan et al. (2018) Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. Proc Natl Acad Sci U S A 115:11808-11813
Yang, Jun; LeBlanc, Francis R; Dighe, Shubha A et al. (2018) TRAIL mediates and sustains constitutive NF-?B activation in LGL leukemia. Blood 131:2803-2815

Showing the most recent 10 out of 539 publications